MedTrace Logo

An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

NCT01930786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 744

Last updated 2019-02-11

No results posted yet for this study

Summary

This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.

Conditions

  • Muscle Spasticity

Interventions

DRUG

onabotulinumtoxinA

onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Aleks Zuzek · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-16
Primary Completion
2017-10-09
Completion
2017-10-09

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930786 on ClinicalTrials.gov